LOGO
LOGO

drug development

  • fdagenetherapy 10122025 lg FDA Approves First Gene Therapy Treatment For Rare Immune Disorder Wiskott-Aldrich Syndrome December 10, 2025 05:52 ET

    The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of a rare, genetic immune disorder Wiskott-Aldrich syndrome, or WAS. Waskyra is indicated for pediatric patients six months and older and adults with WAS who...

  • fdadrug 10122025 lg FDA Approves First Drug Under Program To Strengthen US Antibiotic Manufacturing December 10, 2025 04:19 ET

    The U.S. Food and Drug Administration has approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner's National Priority Voucher pilot program, marking the first approval achieved through this review pathway. The approval was completed in just two months, representing a major reduction of the review timeline for this type of application. "Over the last few decades, America l

  • fda 09122025 lg FDA Approves First Cellular Therapy To Treat Severe Aplastic Anemia December 09, 2025 07:43 ET

    The U.S. Food and Drug Administration announced that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic...

  • usukmedicines 03122025 lg US Announces Agreement With UK On Pharmaceutical Pricing December 03, 2025 07:07 ET

    The Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services have announced that the U.S. Government has reached an agreement in principle on pharmaceutical pricing with the United Kingdom. In the U.S.-U.K. Economic Prosperity Deal,...

  • europeanantibiotics 12112025 lg Growing Crisis In European Supply Of Essential Antibiotics, Report Warns November 12, 2025 02:18 ET

    Antibiotics remain vital to modern medicine, yet the report by Newmarket Strategy, a Healthcare consultancy, warned that reliable access is under growing threat, with experts urging immediate policy reforms. Specifically, the report emphasised the growing threat to the sustainable European supply...

  • fdadrug 30102023 lg FDA Moves To Accelerate Biosimilar Development And Lower Drug Costs October 30, 2025 05:12 ET

    The U.S. Food and Drug Administration has announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost "generic" alternatives to biologic drugs that treat serious and chronic diseases. In a new draft guidance, the FDA proposes major updates to...

  • who 13102025 lg WHO Warns Of Widespread Resistance To Common Antibiotics Globally October 13, 2025 08:12 ET

    One in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments, according to a new report by the World Health Organization.. Between 2018 and 2023, antibiotic resistance rose in more than 40 percent of the pathogen-antibiotic combinations monitored, with an average annual increase of 5-15 percent, says the report

  • SCYNEXIS Reports Positive Phase 1 Results For Antifungal Candidate SCY-247 September 30, 2025 10:51 ET

    SCYNEXIS (SCYX) Tuesday reported positive Phase 1 results for its next-generation triterpenoid antifungal for invasive fungal infections, SCY-247. SCY-247 was well tolerated, with only mild to moderate adverse events reported in the study, which involved 88 healthy participants.

  • medicine 26092025 lg Trump Warns Of 100% Tariff On Some Imported Drugs September 26, 2025 07:44 ET

    President Donald Trump has announced that he will impose 100 percent tariff on imports of brand-name or patented pharmaceutical products from next month unless the drug manufacturing company establishes a production plant in the United States. "Starting October 1st, 2025, we will be imposing a 100%...

  • cdc 25092025 lg CDC Report Finds Sharp Rise In Dangerous Drug-Resistant Bacteria September 25, 2025 07:27 ET

    A new report from the Centers for Disease Control and Prevention highlights a dramatic increase in a dangerous type of drug-resistant bacteria called NDM-producing carbapenem-resistant Enterobacterales, or NDM-CRE. The report, titled 'Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales,...

  • opioidsfda 09112025 lg FDA Issues New Guidance To Expand Non-Opioid Options For Chronic Pain, Curb Misuse September 11, 2025 08:03 ET

    As part of its broader strategy to address the opioid crisis, the U.S. Food and Drug Administration has issued draft guidance titled 'Development of Non-Opioid Analgesics for Chronic Pain' to accelerate safe and effective non-opioid treatments and to reduce prescription-related opioid misuse. The...

  • GSK: Gepotidacin Accepted For FDA Priority Review For Uncomplicated Urogenital Gonorrhoea August 11, 2025 02:46 ET

    British drug major GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral option for the treatment of uncomplicated urogenital gonorrhoea in patients 12 years of age and older. The...

  • prescriptiondrugsprice 01082025 lg Trump Urges Pharmaceutical Companies To Cut Prescription Drugs Prices August 01, 2025 07:36 ET

    President Donald Trump has sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nation, known as the most-favored-nation, or MFN, price. Trump called on manufacturers to provide MFN prices to every single Medicaid patient. In the letter, the

  • Akeso: China's NMPA Accepts Ivonescimab + Chemo SNDA As First-Line Treatment For Advanced Sq-NSCLC July 28, 2025 01:06 ET

    Biopharmaceutical company Akeso Inc. (AKESF) announced Monday that China's National Medical Products Administration or NMPA has accepted the supplementary New Drug Application or sNDA for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced...

  • Novartis' Coartem Baby Gets Swissmedic Approval For Malaria In Newborn Babies, Young Infants July 08, 2025 02:11 ET

    Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Tuesday that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The company added that eight African countries also participated in the...

Global Economics Weekly Update - January 26 - 29, 2026

January 30, 2026 15:51 ET
The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.

Latest Updates on COVID-19